The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 20.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 35% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28.
AMN Healthcare Services, Inc.
AMN · the NYSE · USD · Market cap $1.8B · 2,664 employees
AMN Healthcare Services, Inc.
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 20:08 UTC · 15 Nov · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price38.02 USD at the 13 Nov 2026 close
- Our value readOvervalued vs our fair value, as of 13 Nov 2026
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 2.64)
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $22.51 to $25.89, base estimate $22.51 (screen dated 2026-11-13).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 2.64, read 2026-11-14
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
AMN Healthcare Services, Inc. holds its Distribution at $38.02. Consolidating, no directional conviction, held for 5 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 5 days |
| Price at the screen | $38.02 |
| Valuation | 17.69 trailing · 50.51 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 0.45 |
Five Screens, Shown in Full
Does not pass. Debt ratio
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 38.36% | Below 33% | Interest-bearing debt is 38.4% of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 22.18% | Below 49% | Money owed to the company is 22.2% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
AMN Healthcare Services,'s business is in a permissible area, but its interest-bearing debt is about 38% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when AMN's ethical verdict changes
Today AMN does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 13 Nov 2026: it trades above our $22.51 fair value estimate, 2.30% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. The price runs 68.9% above the base estimate.
Third-party analyst targets: 7 covering, consensus Hold. The average target sits −5% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & ProjectionsWhere our models see it going: fair-value estimate $22.51, with a range of $22.51 to $25.89, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsNurse staffing surge meets losses and lofty price
Picture a hospital ward short on nurses during the pandemic rush. AMN stepped in with workforce solutions and saw revenue double in a year. Yet the business now trades at 32 times forward earnings while margins sit at minus 1 percent and return on equity is negative. Fair value sits well below the current price and analysts see limited upside from here, so the opportunity rating stays at none.
The ethical screen clears without issue. That single positive does not offset the weak profitability or the stretched valuation after such rapid growth. Healthcare staffing volumes can swing sharply once emergency demand fades, leaving the company exposed to a quick reversal in both top line and cash generation.
High multiples on shrinking or negative earnings often signal the market has yet to price in the downturn. The setup leaves little room for error. Analysis, not advice.
| Forward P/E | 50.5xexpensive even after accounting for its growth |
| Trailing P/E | 17.7xreasonably valued |
| EPS, trailing | 2.68 |
| EPS, forward | 0.94 |
| Revenue growth | +2.3%slow but positive growth |
| Profit margin | 3.1%barely profitable |
| Return on equity | 15.6%a solid return on shareholder capital |
| FCF yield | 24.27% |
| Debt to equity | 1.05a meaningful debt load worth watching |
| Current ratio | 1.13adequate liquidity, worth monitoring |
| Beta | 0.45barely tracks the market's swings |
| Short interest, float | 0.12% |
| 52-week range | 14.97 - 49.62 |
| Market cap | $1.8B |
| Employees | 2,664 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeAMN trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 90% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 3.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 90% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 90% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 90% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 90% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 90% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 90% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 90% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 17.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 90% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Here's Why You Should Retain AMN Stock in Your Portfolio for Now Yahoo Finance · 3d ago
- Eaton (ETN) Will Supply Hydraulic And Fuel Systems For A New Business Jet Yahoo Finance · 4d ago
- AMN Q3 2026 deep dive: strong Nurse and Allied demand offsets international headwinds Yahoo Finance · 6d ago
- AMN Healthcare Services (AMN) stock trades down, here is why Yahoo Finance · 6d ago
- AMN Healthcare (AMN) Upgraded to Buy: What Does It Mean for the Stock? Yahoo Finance · 6d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $30.27 | -2.4% | · | $977 | -2.4% |
| 2 months | $17.87 | +65.4% | · | $1,654 | +65.4% |
| 3 months | $19.38 | +52.5% | · | $1,525 | +52.5% |
| 6 months | $16.27 | +81.7% | · | $1,817 | +81.7% |
| 1 year | $22.02 | +34.2% | · | $1,342 | +34.2% |
| 2 years | $52.59 | -43.8% | · | $562 | -43.8% |
| 3 years | $106.00 | -72.1% | · | $279 | -72.1% |
| 5 years | $95.73 | -69.1% | · | $309 | -69.1% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever AMN does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.